Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders

Behavioral Sciences

Volumn 4, Issue 2, 2014, Pages 125-153

  Boules, Mona M ^a   Fredrickson, Paul ^a   Muehlmann, Amber M ^b   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction; Animal models; Antipsychotic drugs; Autism spectrum disorder; Neurotensin; Schizophrenia

Indexed keywords

EID: 84926462560     PISSN: None     EISSN: 2076328X     Source Type: Journal    
DOI: 10.3390/bs4020125     Document Type: Review

References (237)

1. Carraway, R.; Bhatnagar, Y.M. Isolation, structure and biologic activity of chicken intestinal neurotensin. Peptides 1980, 1, 167–174.
2. Hermans, E.; Maloteaux, J.M. Mechanisms of regulation of neurotensin receptors. Pharmacol. Ther. 1998, 79, 89–104.
3. Mazella, J. Sortilin/neurotensin receptor-3: A new tool to investigate neurotensin signaling and cellular trafficking? Cell Signal. 2001, 13, 1–6.
4. Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990, 4, 847–854.
5. Chalon, P.; Vita, N.; Kaghad, M.; Guillemot, M.; Bonnin, J.; Delpech, B.; Le Fur, G.; Ferrara, P.; Caput, D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 1996, 386, 91–94.
6. Mazella, J.; Botto, J.M.; Guillemare, E.; Coppola, T.; Sarret, P.; Vincent, J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 1996, 16, 5613–5620.
7. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Dumont, X.; Kaghad, M.; Gully, D.; Le Fur, G.; Ferrara, P.; Caput, D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 1993, 317, 139–142.
8. Vincent, J.P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 1999, 20, 302–309.
9. Gilbert, J.A.; Richelson, E. Neurotensin stimulates formation of cyclic GMP in murine neuroblastoma clone N1E-115. Eur. J. Pharmacol. 1984, 99, 245–246.
10. Watson, M.A.; Yamada, M.; Cusack, B.; Veverka, K.; Bolden-Watson, C.; Richelson, E. The rat neurotensin receptor expressed in Chinese hamster ovary cells mediates the release of inositol phosphates. J. Neurochem. 1992, 59, 1967–1970.
11. Yamada, M.; Richelson, E. Role of signal transduction systems in neurotensin receptor down-regulation induced by agonist in murine neuroblastoma clone N1E-115 cells. J. Pharmacol. Exp. Ther. 1993, 267, 128–133.
12. Hermans, E.; Gailly, P.; Octave, J.N.; Maloteaux, J.M. Rapid desensitization of agonist-induced calcium mobilization in transfected PC12 cells expressing the rat neurotensin receptor. Biochem. Biophys. Res. Commun. 1994, 198, 400–407.
13. Slusher, B.S.; Zacco, A.E.; Maslanski, J.A.; Norris, T.E.; McLane, M.W.; Moore, W.C.; Rogers, N.E.; Ignarro, L.J. The cloned neurotensin receptor mediates cyclic GMP formation when coexpressed with nitric oxide synthase cDNA. Mol. Pharmacol. 1994, 46, 115–121.
14. Poinot-Chazel, C.; Portier, M.; Bouaboula, M.; Vita, N.; Pecceu, F.; Gully, D.; Monroe, J.G.; Maffrand, J.P.; Le Fur, G.; Casellas, P. Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem. J. 1996, 320, 145–151.
15. Lopez Ordieres, M.G.; Rodriguez de Lores Arnaiz, G. Neurotensin inhibits neuronal Na+, K+-ATPase activity through high affinity peptide receptor. Peptides 2000, 21, 571–576.
16. Trudeau, L.E. Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: Evidence for the involvement of multiple receptors. Neuroscience 2000, 97, 293–302.
17. St-Gelais, F.; Jomphe, C.; Trudeau, L.E. The role of neurotensin in central nervous system pathophysiology: What is the evidence? J. Psychiatry Neurosci. 2006, 31, 229–245.
18. Mazella, J.; Vincent, J.P. Functional roles of the NTS2 and NTS3 receptors. Peptides 2006, 27, 2469–2475.
19. Sarret, P.; Krzywkowski, P.; Segal, L.; Nielsen, M.S.; Petersen, C.M.; Mazella, J.; Stroh, T.; Beaudet, A. Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system. J. Comp. Neurol. 2003, 461, 483–505.
20. Martin, S.; Vincent, J.P.; Mazella, J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J. Neurosci. 2003, 23, 1198–1205.
21. Mustain, W.C.; Rychahou, P.G.; Evers, B.M. The role of neurotensin in physiologic and pathologic processes. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18, 75–82.
22. Boules, M.; Li, Z.; Smith, K.; Fredrickson, P.; Richelson, E. Diverse roles of neurotensin agonists in the central nervous system. Front. Endocrinol. 2013, 4, 1–16.
23. Freedman, R. Schizophrenia. New Engl. J. Med. 2003, 349, 1738–1749.
24. Lewis, D.A.; Lieberman, J.A. Catching up on schizophrenia: Natural history and neurobiology. Neuron 2000, 28, 325–334.
25. Newman, S.C.; Bland, R.C. Mortality in a cohort of patients with schizophrenia: A record linkage study. Can. J. Psychiatry 1991, 36, 239–245.
26. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1, 179–186.
27. Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophr. Bull. 2009, 35, 549–562.
28. Snyder, S.H. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am. J. Psychiatry 1976, 133, 197–202.
29. Toda, M.; Abi-Dargham, A. Dopamine hypothesis of schizophrenia: Making sense of it all. Curr. Psychiatry Rep. 2007, 9, 329–336.
30. Carlsson, A.; Waters, N.; Waters, S.; Carlsson, M.L. Network interactions in schizophrenia—Therapeutic implications. Brain Res. Brain Res. Rev. 2000, 31, 342–349.
31. Weinberger, D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44, 660–669.
32. Alagarsamy, S.; Rouse, S.T.; Junge, C.; Hubert, G.W.; Gutman, D.; Smith, Y.; Conn, P.J. NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol. Biochem. Behav. 2002, 73, 299–306.
33. Henry, S.A.; Lehmann-Masten, V.; Gasparini, F.; Geyer, M.A.; Markou, A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43, 1199–1209.
34. Luccini, E.; Musante, V.; Neri, E.; Brambilla Bas, M.; Severi, P.; Raiteri, M.; Pittaluga, A. Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals. Br. J. Pharmacol. 2007, 151, 1087–1094.
35. Tsai, G.; Coyle, J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 165–179.
36. Carlsson, M.; Carlsson, A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia—Implications for schizophrenia and Parkinson’s disease. Trends Neurosci. 1990, 13, 272–276.
37. Marek, G.J.; Behl, B.; Bespalov, A.Y.; Gross, G.; Lee, Y.; Schoemaker, H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain? Mol. Pharmacol. 2010, 77, 317–326.
38. Chartoff, E.H.; Heusner, C.L.; Palmiter, R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005, 30, 1324–1333.
39. Olney, J.W.; Newcomer, J.W.; Farber, N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33, 523–533.
40. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148, 1301–1308.
41. Brody, S.A.; Conquet, F.; Geyer, M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 2004, 172, 187–195.
42. Chiamulera, C.; Epping-Jordan, M.P.; Zocchi, A.; Marcon, C.; Cottiny, C.; Tacconi, S.; Corsi, M.; Orzi, F.; Conquet, F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 2001, 4, 873–874.
43. Lu, Y.M.; Jia, Z.; Janus, C.; Henderson, J.T.; Gerlai, R.; Wojtowicz, J.M.; Roder, J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 1997, 17, 5196–5205.
44. Matosin, N.; Newell, K.A. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2013, 37, 256–268.
45. Homayoun, H.; Stefani, M.R.; Adams, B.W.; Tamagan, G.D.; Moghaddam, B. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacol 2004, 29, 1259–1269.
46. Pietraszek, M.; Gravius, A.; Schafer, D.; Weil, T.; Trifanova, D.; Danysz, W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 2005, 49, 73–85.
47. Vales, K.; Svoboda, J.; Benkovicova, K.; Bubenikova-Valesova, V.; Stuchlik, A. The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801. Eur. J. Pharmacol. 2010, 639, 91–98.
48. Zou, D.; Huang, J.; Wu, X.; Li, L. Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats. Neuropharmacology 2007, 52, 476–486.
49. Robbins, T.W.; Murphy, E.R. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol. Sci. 2006, 27, 141–148.
50. Joyce, J.N. The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacology (Berl) 1993, 112, S16–S34.
51. Tort, A.B.; Souza, D.O.; Lara, D.R. Theoretical insights into the mechanism of action of atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 541–548.
52. Remington, G. Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evid.-based Ment. Health 2009, 12, 51. doi: 10.1136/ebmh.12.2.51.
53. Gardell, L.R.; Vanover, K.E.; Pounds, L.; Johnson, R.W.; Barido, R.; Anderson, G.T.; Veinbergs, I.; Dyssegaard, A.; Brunmark, P.; Tabatabaei, A., et al. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 2007, 322, 862–870.
54. Abbas, A.; Roth, B.L. Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opinion Pharmacother. 2008, 9, 3251–3259.
55. Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192, 481–483.
56. Andersson, C.; Chakos, M.; Mailman, R.; Lieberman, J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatri. Clin. North Am. 1998, 21, 151–179.
57. Salimi, K.; Jarskog, L.F.; Lieberman, J.A. Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs 2009, 23, 837–855.
58. Cordoba, O.A. Antipsychotic medications: Clinical use and effectiveness. Hosp Pract (Off Ed) 1981, 16, 99–101.
59. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251, 238–246.
60. Meltzer, H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64, 393–406.
61. Kane, J.M. Addressing side effects from antipsychotic treatment in schizophrenia. J. Clinic. Psychiatr. 2011, 72, e07. doi: 10.4088/JCP.9101tx3c.
62. Krystal, J.H.; Mathew, S.J.; D’Souza, D.C.; Garakani, A.; Gunduz-Bruce, H.; Charney, D.S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24, 669–693.
63. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat. Med. 2007, 13, 1102–1107.
64. Gray, L.; van den Buuse, M.; Scarr, E.; Dean, B.; Hannan, A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol. 2009, 12, 45–60.
65. Matosin, N.; Frank, E.; Deng, C.; Huang, X.F.; Newell, K.A. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr. Res. 2013, 146, 170–176.
66. Iasevoli, F.; Tomasetti, C.; Marmo, F.; Bravi, D.; Arnt, J.; de Bartolomeis, A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology 2010, 212, 329–344.
67. Greenbaum, D.; Colangelo, C.; Williams, K.; Gerstein, M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 2003, 4, 117. doi: 10.1186/gb-2003-4-9-117.
68. Polese, D.; de Serpis, A.A.; Ambesi-Impiombato, A.; Muscettola, G.; de Bartolomeis, A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacol. 2002, 27, 906–913.
69. Shao, F.; Han, X.; Li, N.; Wang, W. Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats. Eur. J. Pharmacol. 2010, 649, 202–205.
70. D’Souza, D.C.; Singh, N.; Elander, J.; Carbuto, M.; Pittman, B.; Udo de Haes, J.; Sjogren, M.; Peeters, P.; Ranganathan, M.; Schipper, J. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacol. 2012, 37, 1036–1046.
71. Alberati, D.; Moreau, J.L.; Lengyel, J.; Hauser, N.; Mory, R.; Borroni, E.; Pinard, E.; Knoflach, F.; Schlotterbeck, G.; Hainzl, D., et al. Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 2012, 62, 1152–1161.
72. Lane, H.Y.; Chang, Y.C.; Liu, Y.C.; Chiu, C.C.; Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatr. 2005, 62, 1196–1204.
73. Lane, H.Y.; Lin, C.H.; Huang, Y.J.; Liao, C.H.; Chang, Y.C.; Tsai, G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13, 451–460.
74. Tsai, G.; Lane, H.Y.; Yang, P.; Chong, M.Y.; Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatr. 2004, 55, 452–456.
75. Citrome, L.; Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs 2011, 25, 1009–1021.
76. Chue, P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: Focus on the glycine transporter 1 (GlyT1). Curr. Pharm. Des. 2013, 19, 1311–1320.
77. Noetzel, M.J.; Jones, C.K.; Conn, P.J. Emerging approaches for treatment of schizophrenia: Modulation of glutamatergic signaling. Discov. Med. 2012, 14, 335–343.
78. Krebs, M.; Leopold, K.; Hinzpeter, A.; Schaefer, M. Current schizophrenia drugs: Efficacy and side effects. Expert Opinion Pharmacother. 2006, 7, 1005–1016.
79. Brouard, A.; Pelaprat, D.; Dana, C.; Vial, M.; Lhiaubet, A.M.; Rostene, W. Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J. Neurosci. 1992, 12, 1409–1415.
80. Palacios, J.M.; Kuhar, M.J. Neurotensin receptors are located on dopamine-containing neurones in rat midbrain. Nature 1981, 294, 587–589.
81. Alexander, M.J.; Leeman, S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J. Comp. Neurol. 1998, 402, 475–500.
82. Kinkead, B.; Nemeroff, C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int. Rev. Neurobiol. 2004, 59, 327–349.
83. Shi, W.X.; Bunney, B.S. Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity. Brain Res. 1991, 543, 315–321.
84. Quirion, R.; Rowe, W.B.; Lapchak, P.A.; Araujo, D.M.; Beaudet, A. Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems. Annu. N. Y. Acad. Sci. 1992, 668, 109–119.
85. Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 2001, 53, 453–486.
86. Fawaz, C.S.; Martel, P.; Leo, D.; Trudeau, L.E. Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. BMC Neurosci. 2009, 10, 96. doi: 10.1186/1471-2202-10-96.
87. Caceda, R.; Kinkead, B.; Nemeroff, C.B. Neurotensin: Role in psychiatric and neurological diseases. Peptides 2006, 27, 2385–2404.
88. Diaz-Cabiale, Z.; Fuxe, K.; Narvaez, J.A.; Finetti, S.; Antonelli, T.; Tanganelli, S.; Ferraro, L. Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: Counteraction by a NTR1-like receptor antagonist. Neuroreport 2002, 13, 763–766.
89. Fuxe, K.; Von Euler, G.; Agnati, L.F.; Merlo Pich, E.; O’Connor, W.T.; Tanganelli, S.; Li, X.M.; Tinner, B.; Cintra, A.; Carani, C.; et al. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Annu. N.Y. Acad. Sci. 1992, 668, 186–204.
90. Li, X.M.; Ferraro, L.; Tanganelli, S.; O’Connor, W.T.; Hasselrot, U.; Ungerstedt, U.; Fuxe, K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: A receptor binding and microdialysis study. J. Neural. Transm. Gen. Sect. 1995, 102, 125–137.
91. Burgevin, M.C.; Castel, M.N.; Quarteronet, D.; Chevet, T.; Laduron, P.M. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience 1992, 49, 627–633.
92. Burgevin, M.C.; Laduron, P.M.; Quarteronnet, D.; Chevet, T.; Castel, M.N. Striatal injection of neurotensin increases tyrosine hydroxylase mRNA in substantia nigra. Annu. N. Y. Acad. Sci. 1992, 668, 311–313.
93. Borroto-Escuela, D.O.; Ravani, A.; Tarakanov, A.O.; Brito, I.; Narvaez, M.; Romero-Fernandez, W.; Corrales, F.; Agnati, L.F.; Tanganelli, S.; Ferraro, L., et al. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochemi. Biophys. Res. Comm. 2013, 435, 140–146.
94. Carlsson, A.; Waters, N.; Carlsson, M.L. Neurotransmitter interactions in schizophrenia—Therapeutic implications. Biol. Psychiatry 1999, 46, 1388–1395.
95. O’Connor, W.T. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J. Neurosci. Meth. 2001, 109, 31–39.
96. Ferraro, L.; Tomasini, M.C.; Fuxe, K.; Agnati, L.F.; Mazza, R.; Tanganelli, S.; Antonelli, T. Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides. Brain Res. Rev. 2007, 55, 144–154.
97. Ferraro, L.; Beggiato, S.; Tomasini, M.C.; Fuxe, K.; Tanganelli, S.; Antonelli, T. Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: An in vivo microdialysis study. J. Neurosci. Res. 2011, 89, 1618–1626.
98. Chen, L.; Yung, K.K.; Yung, W.H. Neurotensin selectively facilitates glutamatergic transmission in globus pallidus. Neuroscience 2006, 141, 1871–1878.
99. Matsuyama, S.; Fukui, R.; Higashi, H.; Nishi, A. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling. Eur. J. Neurosci. 2003, 18, 1247–1253.
100. Ferraro, L.; Tomasini, M.C.; Fernandez, M.; Bebe, B.W.; O’Connor, W.T.; Fuxe, K.; Glennon, J.C.; Tanganelli, S.; Antonelli, T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: A dual-probe microdialysis study in intact conscious rat brain. Neuroscience 2001, 102, 113–120.
101. Ferraro, L.; Tomasini, M.C.; Siniscalchi, A.; Fuxe, K.; Tanganelli, S.; Antonelli, T. Neurotensin increases endogenous glutamate release in rat cortical slices. Life Sci. 2000, 66, 927–936.
102. Sanz, B.; Exposito, I.; Mora, F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport 1993, 4, 1194–1196.
103. Tanganelli, S.; O’Connor, W.T.; Ferraro, L.; Bianchi, C.; Beani, L.; Ungerstedt, U.; Fuxe, K. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 1994, 60, 649–657.
104. Kinkead, B.; Shahid, S.; Owens, M.J.; Nemeroff, C.B. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. J. Pharmacol. Exp. Ther. 2000, 295, 67–73.
105. Levant, B.; Nemeroff, C.B. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802. J. Pharmacol. Exp. Ther. 1992, 262, 348–355.
106. Merchant, K.M.; Dobner, P.R.; Dorsa, D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 1992, 12, 652–663.
107. Merchant, K.M.; Miller, M.A.; Ashleigh, E.A.; Dorsa, D.M. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res. 1991, 540, 311–314.
108. Myers, B.; Levant, B.; Bissette, G.; Nemeroff, C.B. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. Brain Res. 1992, 575, 325–328.
109. Merchant, K.M.; Dorsa, D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. USA. 1993, 90, 3447–3451.
110. Bolden-Watson, C.; Watson, M.A.; Murray, K.D.; Isackson, P.J.; Richelson, E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J. Neurochem. 1993, 61, 1141–1143.
111. Giardino, L.; Calza, L.; Piazza, P.V.; Zanni, M.; Amato, G. DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs. Brain Res. 1990, 532, 140–145.
112. Radke, J.M.; MacLennan, A.J.; Beinfeld, M.C.; Bissette, G.; Nemeroff, C.B.; Vincent, S.R.; Fibiger, H.C. Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. Brain Res. 1989, 480, 178–183.
113. Levant, B.; Bissette, G.; Nemeroff, C.B. Effects of anticholinergic drugs on regional brain neurotensin concentrations. Eur. J. Pharmacol. 1989, 165, 327–330.
114. Levant, B.; Bissette, G.; Widerlov, E.; Nemeroff, C.B. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. Regul. Pept. 1991, 32, 193–201.
115. Bissette, G.; Nemeroff, C.B. Neurotensin and the mesocorticolimbic dopamine system. Annu. NY Acad. Sci. 1988, 537, 397–404.
116. See, R.E.; Lynch, A.M.; Aravagiri, M.; Nemeroff, C.B.; Owens, M.J. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Res. 1995, 704, 202–209.
117. Huang, W.; Hanson, G.R. Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems. Eur. J. Pharmacol. 1997, 332, 15–21.
118. Govoni, S.; Hong, J.S.; Yang, H.Y.; Costa, E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J. Pharmacol. Exp. Ther. 1980, 215, 413–417.
119. Merchant, K.M.; Letter, A.A.; Gibb, J.W.; Hanson, G.R. Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol. 1988, 153, 1–9.
120. Gruber, S.H.; Nomikos, G.G.; Mathe, A.A. Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat. Neuropsychopharmacology 2002, 26, 595–604.
121. Bissette, G.; Nemeroff, C.B.; Loosen, P.T.; Prange, A.J.; Lipton, M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature 1976, 262, 607–609.
122. Sarhan, S.; Hitchcock, J.M.; Grauffel, C.A.; Wettstein, J.G. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 1997, 18, 1223–1227.
123. Nemeroff, C.B.; Bissette, G.; Prange, A.J.; Loosen, P.T.; Barlow, T.S.; Lipton, M.A. Neurotensin: Central nervous system effects of a hypothalamic peptide. Brain Res. 1977, 128, 485–496.
124. Nemeroff, C.B.; Levant, B.; Myers, B.; Bissette, G. Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies. Annu. NY Acad. Sci. 1992, 668, 146–156.
125. Jolicoeur, F.B.; de Michele, G.; Barbeau, A.; St-Pierre, S. Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. Neurosci. Biobehav. Rev. 1983, 7, 385–390.
126. Jolicoeur, F.B.; Gagne, M.A.; Rivest, R.; Drumheller, A.; St-Pierre, S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 1993, 32, 487–491.
127. Stoessl, A.J. Effects of neurotensin in a rodent model of tardive dyskinesia. Neuropharmacology 1995, 34, 457–462.
128. Luttinger, D.; Nemeroff, C.B.; Prange, A.J. The effects of neuropeptides on discrete-trial conditioned avoidance responding. Brain Res. 1982, 237, 183–192.
129. Feifel, D.; Minor, K.L.; Dulawa, S.; Swerdlow, N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997, 760, 80–84.
130. Swerdlow, N.R.; Braff, D.L.; Taaid, N.; Geyer, M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 1994, 51, 139–154.
131. Nemeroff, C.B. Neurotensin: Perchance an endogenous neuroleptic? Biol. Psychiatry 1980, 15, 283–302.
132. Kinkead, B.; Binder, E.B.; Nemeroff, C.B. Does neurotensin mediate the effects of antipsychotic drugs? Biol. Psychiatry 1999, 46, 340–351.
133. Cusack, B.; Boules, M.; Tyler, B.M.; Fauq, A.; McCormick, D.J.; Richelson, E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 2000, 856, 48–54.
134. Feifel, D.; Melendez, G.; Shilling, P.D. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology 2003, 28, 651–653.
135. Shilling, P.D.; Richelson, E.; Feifel, D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res. 2003, 143, 7–14.
136. Briody, S.; Boules, M.; Oliveros, A.; Fauq, I.; Richelson, E. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behav. Brain Res. 2010, 207, 118–124.
137. Kinkead, B.; Dobner, P.R.; Egnatashvili, V.; Murray, T.; Deitemeyer, N.; Nemeroff, C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: Restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 2005, 315, 256–264.
138. Feifel, D.; Pang, Z.; Shilling, P.D.; Melendez, G.; Schreiber, R.; Button, D. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology 2010, 58, 173–178.
139. Feifel, D.; Reza, T.L.; Robeck, S.L. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides 1997, 18, 1457–1460.
140. Feifel, D.; Melendez, G; Shilling, P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: A potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 2004, 29, 731–738.
141. Shilling, P.D.; Melendez, G.; Priebe, K; Richelson, E.; Feifel, D. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT(2A) and an alpha(1) agonist. Psychopharmacology (Berl) 2004, 175, 353–359.
142. Secchi, R.L.; Sung, E.; Hedley, L.R.; Button, D.; Schreiber, R. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist but not by dopaminergic agonists. Behav. Brain Res. 2009, 202, 192–197.
143. Geyer, M.A.; Ellenbroek, B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 1071–1079.
144. Binder, E.B.; Kinkead, B.; Owens, M.J.; Kilts, C.D.; Nemeroff, C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating. J. Neurosci. 2001, 21, 601–608.
145. Binder, E.B.; Gross, R.E.; Nemeroff, C.B.; Kilts, C.D. Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. Psychopharmacology (Berl) 2002, 161, 288–295.
146. Boules, M.; Warrington, L.; Fauq, A.; McCormick, D.; Richelson, E. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 426, 73–76.
147. Boules, M.; McMahon, B.; Warrington, L.; Stewart, J.; Jackson, J.; Fauq, A.; McCormick, D.; Richelson, E. Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. Brain Res. 2001, 919, 1–11.
148. Boules, M.; Liang, Y.; Briody, S.; Miura, T.; Fauq, I.; Oliveros, A.; Wilson, M.; Khaniyev, S.; Williams, K.; Li, Z.; et al. NT79: A novel neurotensin analog with selective behavioral effects. Brain Res. 2010, 1308, 35–46.
149. Li, Z.; Boules, M.; Williams, K.; Peris, J.; Richelson, E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res. 2010, 1311, 28–36.
150. Snyder, S.H. Phencyclidine. Nature 1980, 285, 355–356.
151. Feifel, D.; Reza, T.L.; Wustrow, D.J.; Davis, M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 1999, 288, 710–713.
152. Holly, E.N.; Ebrecht, B.; Prus, A.J. The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. Eur. Neuropsychopharmacol 2011, 21, 526–531.
153. Liang, Y.; Boules, M.; Li, Z.; Williams, K.; Miura, T.; Oliveros, A.; Richelson, E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology 2010, 58, 1199–1205.
154. Li, Z.; Liang, Y.; Boules, M.; Gordillo, A.; Richelson, E. Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: A possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia. Neuropharmacology 2010, 58, 1174–1178.
155. Li, Z.; Boules, M.; Williams, K.; Gordillo, A.; Li, S.; Richelson, E. Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: Relevance to schizophrenia. Neurobiol. Dis. 2010, 40, 467–477.
156. Garver, D.L.; Bissette, G.; Yao, J.K.; Nemeroff, C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry. 1991, 148, 484–488.
157. Lindstrom, L.H.; Widerlov, E.; Bisette, G.; Nemeroff, C. Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr. Res. 1988, 1, 55–59.
158. Nemeroff, C.B.; Bissette, G.; Widerlov, E.; Beckmann, H.; Gerner, R.; Manberg, P.J.; Lindstrom, L.; Prange, A.J.; Gattaz, W.F. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome. J. Neuropsychiatry Clin. Neurosci. 1989, 1, 16–20.
159. Sharma, R.P.; Janicak, P.G.; Bissette, G.; Nemeroff, C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 1997, 154, 1019–1021.
160. Widerlov, E.; Lindstrom, L.H.; Besev, G.; Manberg, P.J.; Nemeroff, C.B.; Breese, G.R.; Kizer, J.S.; Prange, A.J. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment. Am. J. Psychiatry. 1982, 139, 1122–1126.
161. Breslin, N.A.; Suddath, R.L.; Bissette, G.; Nemeroff, C.B.; Lowrimore, P.; Weinberger, D.R. CSF concentrations of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates. Schizophr. Res. 1994, 12, 35–41.
162. Binder, E.B.; Kinkead, B.; Owens, M.J; Nemeroff, C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol. Psychiatry 2001, 50, 856–872.
163. Dalack, G.W.; Healy, D.J.; Meador-Woodruff, J.H. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. Am. J. Psychiatry 1998, 155, 1490–1501.
164. Boules, M.; Cusack, B.; Zhao, L.; Fauq, A.; McCormick, D.J.; Richelson, E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 2000, 865, 35–44.
165. Kim, E.R.; Leckstrom, A.; Mizuno, T.M. Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice. Behav. Brain Res. 2008, 194, 66–71.
166. Feifel, D.; Goldenberg, J.; Melendez, G.; Shilling, P.D. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology 2010, 58, 195–198.
167. Koob, G.F.; Sanna, P.P.; Bloom, F.E. Neuroscience of addiction. Neuron 1998, 21, 467–476.
168. Boules, M.; Stennett, B.; Muhktar, N.; Li, Z.; Cai, S.; Richelson, E. Novel Therapy for Nicotine Addiction in Alcohol Dependent Rats. J. Addiction Res. Ther. 2013, 4, 161. doi: 10.4172/2155–6105.1000161.
169. Lee, M.R.; Hinton, D.J.; Song, J.Y.; Lee, K.W.; Choo, C.; Johng, H.; Unal, S.S.; Richelson, E.; Choi, D.S. Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice. Pharmacol. Biochem. Behav. 2010, 95, 235–241.
170. Lee, M.R.; Hinton, D.J.; Unal, S.S.; Richelson, E.; Choi, D.S. Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2. Alcohol. Clin. Exp. Res. 2011, 35, 99–107.
171. Miller, D.K.; Wilkins, L.H.; Bardo, M.T.; Crooks, P.A.; Dwoskin, L.P. Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology (Berl) 2001, 156, 469–476.
172. De Vries, T.J.; Schoffelmeer, A.N.; Binnekade, R.; Raaso, H.; Vanderschuren, L.J. Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. Neuropsychopharmacology 2002, 26, 18–26.
173. Domino, E.F. Nicotine induced behavioral locomotor sensitization. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25, 59–71.
174. Kalivas, P. W.; Duffy, P. Dopamine regulation of extracellular glutamate in the nucleus accumbens. Brain research. 1997, 761, 173–177.
175. Iyaniwura, T.T.; Wright, A.E.; Balfour, D.J. Evidence that mesoaccumbens dopamine and locomotor responses to nicotine in the rat are influenced by pretreatment dose and strain. Psychopharmacology (Berl) 2001, 158, 73–79.
176. Balfour, D.J. The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob. Res. 2004, 6, 899–912.
177. Kalivas, P.W.; Duffy, P. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J. Neurosci. 1990, 10, 2940–2949.
178. Richelson, E.; Boules, M.; Fredrickson, P. Neurotensin agonists: Possible drugs for treatment of psychostimulant abuse. Life Sci. 2003, 73, 679–690.
179. Fredrickson, P.; Boules, M.; Yerbury, S.; Richelson, E. Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. Eur. J. Pharmacol. 2003, 458, 111–118.
180. Fredrickson, P.; Boules, M.; Yerbury, S.; Richelson, E. Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization. Brain Res. 2003, 979, 245–248.
181. Boules, M.; Oliveros, A.; Liang, Y.; Williams, K.; Shaw, A.; Robinson, J.; Fredrickson, P.; Richelson, E. A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats. Neuropeptides 2011, 45, 9–16.
182. Hall, F.S.; Centeno, M.; Perona, M.T.; Adair, J.; Dobner, P.R.; Uhl, G.R. Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine. Psychopharmacology (Berl) 2012, 219, 35–45.
183. Krawczyk, M.; Mason, X.; DeBacker, J.; Sharma, R.; Normandeau, C.P.; Hawken, E.R.; di Prospero, C.; Chiang, C.; Martinez, A.; Jones, A.A.; et al. D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats. J. Neurosci. 2013, 33, 11960–11971.
184. Felszeghy, K.; Espinosa, J.M.; Scarna, H.; Berod, A.; Rostene, W.; Pelaprat, D. Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference. Neuropsychopharmacology 2007, 32, 2601–2610.
185. Ramos-Ortolaza, D.L.; Negron, A.; Cruz, D.; Falcon, E.; Iturbe, M.C.; Cajigas, M.H.; Maldonado-Vlaar, C.S. Intra-accumbens shell injections of SR48692 enhanced cocaine self-administration intake in rats exposed to an environmentally-elicited reinstatement paradigm. Brain Res. 2009, 1280, 124–136.
186. Torregrossa, M.M.; Kalivas, P.W. Neurotensin in the ventral pallidum increases extracellular gamma-aminobutyric acid and differentially affects cue- and cocaine-primed reinstatement. J. Pharmacol. Exp. Ther. 2008, 325, 556–566.
187. Gendron, L.; Perron, A.; Payet, M.D.; Gallo-Payet, N.; Sarret, P.; Beaudet, A. Low-Affinity Neurotensin Receptor (NTS2) Signaling: Internalization-Dependent Activation of Extracellular Signal-Regulated Kinases 1/2. Mol. Pharmacol. 2004, 66, 1421–1430.
188. Gruber, S.H.; Nomikos, G.G.; Mathe, A.A. d-Amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors. J. Neurosci. Res. 2002, 69, 133–139.
189. Hertel, P.; Mathe, J.M.; Nomikos, G.G.; Iurlo, M.; Mathe, A.A.; Svensson, T.H. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 1995, 72, 103–114.
190. Panayi, F.; Colussi-Mas, J.; Lambas-Senas, L.; Renaud, B.; Scarna, H.; Berod, A. Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization. Neuropsychopharmacology 2005, 30, 871–879.
191. Rompre, P.; Perron, S. Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology 2000, 39, 1880–1892.
192. Panayi, F.; Dorso, E.; Lambas-Senas, L.; Renaud, B.; Scarna, H.; Berod, A. Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioral response to D-amphetamine. Neuropsychopharmacology 2002, 26, 64–74.
193. Costa, F.G.; Frussa-Filho, R.; Felicio, L.F. The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur. J. Pharmacol. 2001, 428, 97–103.
194. Feifel, D.; Melendez, G.; Murray, R.J.; Tina Tran, D.N.; Rullan, M.A.; Shilling, P.D. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology (Berl) 2008, 200, 197–203.
195. Fleckenstein, A.E.; Volz, T.J.; Riddle, E.L.; Gibb, J.W.; Hanson, G.R. New insights into the mechanism of action of amphetamines. Ann. Rev. Pharmacol. Toxicol. 2007, 47, 681–698.
196. Frankel, P.S.; Hoonakker, A.J.; Alburges, M.E.; McDougall, J.W.; McFadden, L.M.; Fleckenstein, A.E.; Hanson, G.R. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J. Pharmacol. Exp. Therapeut. 2011, 336, 809–815.
197. Wagstaff, J.D.; Gibb, J.W.; Hanson, G.R. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. J. Pharmacol. Exp. Ther. 1996, 278, 547–554.
198. Frankel, P.S.; Alburges, M.E.; Bush, L.; Hanson, G.R.; Kish, S.J. Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology 2007, 53, 447–454.
199. Ehlers, C.L.; Somes, C.; Li, T.K.; Lumeng, L.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. Neurontensin studies in alcohol naive, preferring and non-preferring rats. Neuroscience 1999, 93, 227–236.
200. Li, Z.; Boules, M.; Richelson, E. NT69L blocks ethanol-induced increase of dopamine and glutamate levels in striatum of mouse. Neurosci. Lett. 2011, 487, 322–324.
201. Boules, M.; Fredrickson, P.; Richelson, E. Bioactive analogs of neurotensin. Peptides 2006, 27, 2523–2533.
202. American Pschiatric Association, ed. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.
203. Lam, K.S.; Bodfish, J.W.; Piven, J. Evidence for three subtypes of repetitive behavior in autism that differ in familiality and association with other symptoms. J. Child Psychol. Psychiatry Allied Discip. 2008, 49, 1193–1200.
204. Ghosh, A.; Michalon, A.; Lindemann, L.; Fontoura, P.; Santarelli, L. Drug discovery for autism spectrum disorder: Challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12, 777–790.
205. Nemeroff, C.B.; Luttinger, D.; Hernandez, D.E.; Mailman, R.B.; Mason, G.A.; Davis, S.D.; Widerlov, E.; Frye, G.D.; Kilts, C.A.; Beaumont, K.; et al. Interactions of neurotensin with brain dopamine systems: Biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 1983, 225, 337–345.
206. Casanova, M.F.; Naidu, S.; Goldberg, T.E.; Moser, H.W.; Khoromi, S.; Kumar, A.; Kleinman, J.E.; Weinberger, D.R. Quantitative magnetic resonance imaging in Rett syndrome. J. Neuropsychiatry Clin. Neurosci. 1991, 3, 66–72.
207. Reiss, A.L.; Abrams, M.T.; Greenlaw, R.; Freund, L.; Denckla, M.B. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat. Med. 1995, 1, 159–167.
208. Harris, J.C.; Lee, R.R.; Jinnah, H.A.; Wong, D.F.; Yaster, M.; Bryan, R.N. Craniocerebral magnetic resonance imaging measurement and findings in Lesch-Nyhan syndrome. Arch. Neurol. 1998, 55, 547–553.
209. Hollander, E.; Anagnostou, E.; Chaplin, W.; Esposito, K.; Haznedar, M.M.; Licalzi, E.; Wasserman, S.; Soorya, L.; Buchsbaum, M. Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol. Psychiatr. 2005, 58, 226–232.
210. Rojas, D.C.; Peterson, E.; Winterrowd, E.; Reite, M.L.; Rogers, S.J.; Tregellas, J.R. Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms. BMC Psychiatry 2006, 6, 56. doi: 10.1186/1471-244X-6-56.
211. Hoeft, F.; Hernandez, A.; Parthasarathy, S.; Watson, C.L.; Hall, S.S.; Reiss, A.L. Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome. Hum. Brain Mapp. 2007, 28, 543–554.
212. Langen, M.; Schnack, H.G.; Nederveen, H.; Bos, D.; Lahuis, B.E.; de Jonge, M.V.; van Engeland, H.; Durston, S. Changes in the developmental trajectories of striatum in autism. Biol. Psychiatr. 2009, 66, 327–333.
213. Wolff, J.J.; Hazlett, H.C.; Lightbody, A.A.; Reiss, A.L.; Piven, J. Repetitive and self-injurious behaviors: Associations with caudate volume in autism and fragile X syndrome. J. Neurodev. Disord. 2013, 5, 12. doi: 10.1186/1866-1955-5-12.
214. Ferraro, L.; Antonelli, T.; O’Connor, W.T.; Fuxe, K.; Soubrie, P.; Tanganelli, S. The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: Functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J. Neurosci. 1998, 18, 6977–6989.
215. Chen, L.; Yung, K.K.; Yung, W.H. Neurotensin depolarizes globus pallidus neurons in rats via neurotensin type-1 receptor. Neuroscience 2004, 125, 853–859.
216. Welch, J.M.; Lu, J.; Rodriguiz, R.M.; Trotta, N.C.; Peca, J.; Ding, J.D.; Feliciano, C.; Chen, M.; Adams, J.P.; Luo, J.; et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448, 894–900.
217. El-Kordi, A.; Winkler, D.; Hammerschmidt, K.; Kastner, A.; Krueger, D.; Ronnenberg, A.; Ritter, C.; Jatho, J.; Radyushkin, K.; Bourgeron, T.; et al. Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism. Behav. Brain Res. 2013, 251, 41–49.
218. Greco, B.; Manago, F.; Tucci, V.; Kao, H.T.; Valtorta, F.; Benfenati, F. Autism-related behavioral abnormalities in synapsin knockout mice. Behav. Brain Res. 2013, 251, 65–74.
219. Uchino, S.; Waga, C. SHANK3 as an autism spectrum disorder-associated gene. Brain Dev. 2013, 35, 106–110.
220. Presti, M.F.; Lewis, M.H. Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior. Behav. Brain Res. 2005, 157, 363–368.
221. Tanimura, Y.; King, M.A.; Williams, D.K.; Lewis, M.H. Development of repetitive behavior in a mouse model: Roles of indirect and striosomal basal ganglia pathways. Int. J. Dev. Neurosci. 2011, 29, 461–467.
222. Muehlmann, A.M.; Buchwald, Z.; Edington, G.; Lewis, M.H. Neuronal hypoactivation of the subthalamic nucleus in an inbred model of restricted, repetitive behavior. Available online: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=29b0782c-eec2-44c2-8e90-f767543e080f&cKey=6a02ee69-3e68-479d-b17b-2306bfa9eaba&mKey=%7b8D2A5BEC-4825-4CD 6-9439-B42BB151D1CF%7d (accessed on 12 June 2014).
223. Turner, C.A.; Lewis, M.H.; King, M.A. Environmental enrichment: Effects on stereotyped behavior and dendritic morphology. Dev. Psychobiol. 2003, 43, 20–27.
224. Tanimura, Y.; Vaziri, S.; Lewis, M.H. Indirect basal ganglia pathway mediation of repetitive behavior: Attenuation by adenosine receptor agonists. Behav. Brain Res. 2010, 210, 116–122.
225. Muehlmann, A.M.; Edington, G.; Mihalik, A.C.; Buchwald, Z.; Koppuzha, D.; Korah, M.; Lewis, M.H. Further characterization of repetitive behavior in C58 mice: Developmental trajectory and effects of environmental enrichment. Behav. Brain Res. 2012, 235, 143–149.
226. Ghanizadeh, A. Targeting neurotensin as a potential novel approach for the treatment of autism. J. Neuroinflammation. 2010, 7, 58. doi: 10.1186/1742-2094-7-58.
227. Angelidou, A.; Francis, K.; Vasiadi, M.; Alysandratos, K.D.; Zhang, B.; Theoharides, A.; Lykouras, L.; Sideri, K.; Kalogeromitros, D.; Theoharides, T.C. Neurotensin is increased in serum of young children with autistic disorder. J. Neuroinflammation 2010, 7, 48. doi: 10.1186/1742-2094-7-48.
228. Zhang, B.; Angelidou, A.; Alysandratos, K.D.; Vasiadi, M.; Francis, K.; Asadi, S.; Theoharides, A.; Sideri, K.; Lykouras, L.; Kalogeromitros, D.; et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. J. Neuroinflammation. 2010, 7, 80. doi: 10.1186/1742-2094-7-80.
229. Koon, H.W.; Kim, Y.S.; Xu, H.; Kumar, A.; Zhao, D.; Karagiannides, I.; Dobner, P.R.; Pothoulakis, C. Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis. Proceed. Natl. Acad. Sci. USA. 2009, 106, 8766–8771.
230. Li, X.; Chauhan, A.; Sheikh, A.M.; Patil, S.; Chauhan, V.; Li, X.M.; Ji, L.; Brown, T.; Malik, M. Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 2009, 207, 111–116.
231. Adams, J.B.; Johansen, L.J.; Powell, L.D.; Quig, D.; Rubin, R.A. Gastrointestinal flora and gastrointestinal status in children with autism—Comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011, 11, 22. doi: 10.1186/1471-230X-11-22.
232. Thomas, R.P.; Hellmich, M.R.; Townsend, C.M., Jr.; Evers, B.M. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr. Rev. 2003, 24, 571–599.
233. Kim, E.R.; Mizuno, T.M. Role of neurotensin receptor 1 in the regulation of food intake by neuromedins and neuromedin-related peptides. Neurosci. Lett. 2010, 468, 64–67.
234. Sharp, W.G.; Berry, R.C.; McCracken, C.; Nuhu, N.N.; Marvel, E.; Saulnier, C.A.; Klin, A.; Jones, W.; Jaquess, D.L. Feeding problems and nutrient intake in children with autism spectrum disorders: A meta-analysis and comprehensive review of the literature. J. Autism Dev. Disord. 2013, 43, 2159–2173.
235. Tordjman, S.; Anderson, G.M.; Botbol, M.; Brailly-Tabard, S.; Perez-Diaz, F.; Graignic, R.; Carlier, M.; Schmit, G.; Rolland, A.C.; Bonnot, O.; et al. Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder. PloS One 2009, 4, e5289. doi: 10.1371/journal.pone.0005289.
236. Wang, R.; Boules, M.; Gollatz, E.; Williams, K.; Tiner, W.; Richelson, E. Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain. Brain Res. Mol. Brain Res. 2005, 138, 24–34.
237. Perron, A.; Sharif, N.; Gendron, L.; Lavallee, M.; Stroh, T.; Mazella, J.; Beaudet, A. Sustained neurotensin exposure promotes cell surface recruitment of NTS2 receptors. Biochem. Biophys. Res. Commun. 2006, 343, 799–808.